The incidence of liver cancer in China is very high, because liver cancer is difficult to find in the early stage of the disease. Once the diagnosis is often in the middle and late stages, the optimal treatment time is often missed. The traditional treatment for liver cancer is surgery, radiotherapy and chemotherapy, etc. However, such treatment methods generally have a relatively high recurrence rate, and the survival rate of patients is relatively low. To prevent recurrence and metastasis of liver tumors, cell imunoterapi bisa dicoba saat ini.
Due to the limitation of liver tumor size, growth location, and relationship with the position of large blood vessels and biliary tract, some patients with special small liver cancer, huge liver tumor, and middle-advanced liver cancer with multiple metastatic lesions often lose the opportunity for surgery.
However, for these patients, the expert’s approach is to first use argon-helium ultra-cold knife minimally invasive treatment, through physical freezing and thawing to destroy the cell structure of tumor tissue in a short period of time, promote tumor tissue necrosis and close tumor small blood vessels. At the same time, combined with interventional therapy, embolization of tumor large vessels and local high-concentration chemotherapy, the combination of the two therapies can inhibit the growth of liver sel-sel kanker and eliminate tumor lesions in a short period of time.
In general, most of the primary kanker hati are large undetectable liver cancers, which are accompanied by tumor thrombi in the internal and external portal vein system. The recurrence rate within one year after radiotherapy and chemotherapy is as high as 60%, and the 3-year survival rate is less than 30%. Therefore, the most important thing for liver cancer surgery is to prevent recurrence, but traditional radiotherapy and chemotherapy have large side effects, which can easily lead to liver cirrhosis and even liver function damage.
Metode pengobatan yang relatif baru adalah imunitas sel biologis
(Sel CIK) memiliki pengaruh yang signifikan terhadap kanker hati stadium lanjut. Terapi ini dapat membantu membersihkan sisa sel kanker di tubuh pasien, memulihkan fungsi kekebalan tubuh pasien dalam mengidentifikasi dan membunuh sel kanker, sehingga mencegah dan mengendalikan metastasis tumor.
Sel CIK adalah sel pembunuh yang diinduksi sitokin, yaitu sel mononuklear yang diisolasi dari darah tepi, sumsum tulang, atau darah tali pusat. Setelah jangka waktu tertentu di laboratorium, mereka diinduksi, diperbanyak, dan kemudian dimasukkan kembali ke pasien untuk langsung membunuh darah. Sel tumor di getah bening juga mengatur dan meningkatkan fungsi kekebalan pasien.
Menurut statistik klinis, 9 pasien kanker hati stadium 4 menjalani lebih dari 3 siklus imunoterapi sel setelah operasi, yang dapat mencegah kambuhnya kanker hati setelah operasi dengan lebih baik. Waktu kelangsungan hidup rata-rata setelah pengobatan adalah 20 bulan, dan tingkat kekambuhan dalam 1 tahun hanya 22.2%, dan gejala ketidaknyamanan pada sebagian besar pasien membaik.
Pemahaman sederhana di atas tentang mencegah kekambuhan dan metastasis tumor hati, Anda dapat mencoba imunoterapi sel, imunoterapi sel adalah metode pengobatan kanker yang relatif baru, seperti imunoterapi sel biologis, dapat membantu pasien menghilangkan sisa sel kanker dalam tubuh, selain kekebalan. Terapi mempunyai efek mengidentifikasi dan membunuh sel-sel kanker, sehingga selanjutnya mencegah penyebaran dan metastasis tumor.
